Fosun Pharma is a pharmaceutical company.
Fosun Pharma, founded in May, 1995 and headquartered in Shanghai, is a pharmaceutical distribution, retail and medical service company. The founders are Chen Qiyu and Yao Fang. Listed on the HKEX on October 30, 2012, the company's major shareholders are Shanghai Fosun High Technology (Group) Co., Ltd., HKSCC Nominees Ltd and Hong Kong Securities Clearing Co., Ltd. Rivals that have direct and indirect competition with Fosun Pharma include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
Fosun Pharmaceutical: the new tablet production line of the holding subsidiary passed the GMP compliance inspection
Xuelang environment: affected by the epidemic situation, the subsidiary temporarily stopped production and resumed production
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Fosun Pharmaceutical: the holding subsidiary started the phase II clinical study on the treatment of fs-1502 for non-small cell lung cancer
On May 11, Ping An of China spent 299 million yuan to buy back 6.6972 million a shares
2022 China AI Health 30 Report
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Sichuan Energy Investment Development: RMB 152 million subscription for Principal Guaranteed structured deposit products of Bank of Communications
Jiangsu Province has issued the outline of building a strong province with intellectual property rights, and will be fully built into a strong province with intellectual property rights in 2035
Tesla unveiled a new giant 360mwh Megapack energy storage project
Chengda biology: transfer relevant assets of Benxi human vaccine base to a wholly-owned subsidiary
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Jiuyuan Yinhai: the holding subsidiary has passed the CMMI5 evaluation and certification
Shenghe resources: it plans to acquire 19.9% equity of peak company
Japan launched measures to curb oil prices for the first time, with a subsidy of 3.4 yen per liter
Rongchuang transferred the equity of Wenzhou No. 1 project company, and the transferee was Dexin real estate
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
Jianxin shares: the net profit in 2021 is expected to decrease by 71% - 80% year-on-year